Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24200089 | 0.90 | TBXAS1 (0.42) | TBXAS1PKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL24200170 | 0.86 | TBXAS1 (0.42) | TBXAS1PKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL21455427 | 0.85 | TBXAS1 (0.42) | TBXAS1PKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL23241666 | 0.85 | TBXAS1 (0.42) | TBXAS1PKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL23616962 | 0.80 | TBXAS1 (0.46) | TBXAS1PKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL23617253 | 0.80 | TBXAS1 (0.47) | TBXAS1PKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL7888801 | 0.80 | TBXAS1 (0.49) | TBXAS1PKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL23425588 | 0.78 | TBXAS1 (0.47) | TBXAS1PKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL23241478 | 0.78 | TBXAS1 (0.47) | TBXAS1PKMCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL24200130 | 0.76 | TBXAS1 (0.39) | TBXAS1PKMCYP4F2CYP4A11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | TBXAS1 75/4885PKM 3285/4885CYP4F2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.